[1] Ruggiero SL, Dodson TB, Fantasia J, et al.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update[J]. J Oral Maxillofac Surg, 2014,72(10):1938-1956. [2] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J].中华骨质疏松和骨矿盐疾病杂志,2017,20(5):413-443. [3] Senel FC, Kadioglu Duman M, Muci E, et al.Jaw bone changes in rats after treatment with zoledronate and pamidronate[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010,109(3):385-391. [4] Krüger TB, Sharikabad MN, Herlofson BB.Bisphosphonate-related osteonecrosis of the jaw in four Nordic countries and an indication of under-reporting[J]. Acta Odontol Scand, 2013,71(6):1386-1390. [5] Kim JW, Tatad J, Landayan M, et al.Animal model for medication-related osteonecrosis of the jaw with precedent metabolic bone disease[J]. Bone, 2015, 81:442-448. [6] Kim JW, Cha IH, Kim SJ, et al.Biomarkers for bisphosphonate-related osteonecrosis of the jaw[J]. Clin Implant Dent Relat Res, 2016,18(2):281-291. [7] Goodwin JS, Zhou J, Kuo YF, et al.Risk of jaw osteonecrosis after intravenous bisphosphonates in cancer patients and patients without cancer[J]. Mayo Clin Proc, 2017,92(1):106-113. [8] Kim KY, Zhang X, Cha IH.Identifying a combined biomarker for bisphosphonate-related osteonecrosis of the jaw[J]. Clin Implant Dent Relat Res, 2018,20(2):191-198. [9] 华洪飞, 王宁涛, 张文杰, 等. 双膦酸盐致颌骨坏死的大鼠模型研究[J].口腔颌面外科杂志,2016,26(1):19-24. [10] 刘杰, 唐华. 大鼠双膦酸盐相关性颌骨坏死模型的建立[J].口腔疾病防治,2017,25(2):133-136. [11] 吴世超, 王颖姝, 轩宾, 等. 建立双膦酸盐性颌骨坏死动物模型[J].中国组织工程研究,2017,21(36):5799-5805. [12] Bi Y, Gao Y, Ehirchiou D, et al.Bisphosphonates cause osteonecrosis of the jaw-like disease in mice[J]. Am J Pathol, 2010,177(1):280-290. [13] 张雅蓉, 唐舸, 刘杉, 等. 5种常用大鼠骨质疏松动物模型的特点[J].国际口腔医学杂志,2013,40(5):629-633. [14] Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research[J]. J Bone Miner Res, 2016, 31(1):16-35. [15] Gallagher JC, Tella SH.Prevention and treatment of postmenopausal osteoporosis[J]. Obstet Gynecol Clin North Am, 2008,35(2):301-315. [16] Bliuc D, Tran T, van Geel T, et al. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study[J]. Osteoporos Int, 2019. [17] Abtahi J, Agholme F, Aspenberg P.Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model[J]. Int J Oral Maxillofac Surg, 2013,42(5):632-636. [18] Abtahi J, Agholme F, Sandberg O, et al.Effect of local vs. systemic bisphosphonate delivery on dental implant fixation in a model of osteonecrosis of the jaw[J]. J Dent Res, 2013,92(3):279-283. [19] Kyrgidis A, Vahtsevanos K, Koloutsos G, et al.Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients[J]. J Clin Oncol, 2008,26(28):4634-4638. [20] Polidoro S, Broccoletti R, Campanella G, et al.Effects of bisphosphonate treatment on DNA methylation in osteonecrosis of the jaw[J]. Mutat Res, 2013,757(2):104-113. [21] Borke JL, McAllister B, Harris T, et al. Correlation of changes in the mandible and retina/choroid vasculature of a rat model of BRON[J][J]. J Craniomaxillofac Surg, 2015,43(7):1144-1150. [22] Schwartz HC.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update and CTX[J]. J Oral Maxillofac Surg, 2015,73(3):377. [23] Marx RE, Tursun R.Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease[J]. Int J Oral Maxillofac Surg, 2012,41(3):283-289. [24] Fedele S, Bedogni G, Scoletta M, et al.Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed[J]. Br J Oral Maxillofac Surg, 2015,53(1):13-17. [25] Migliario M, Mergoni G, Vescovi P, et al.Osteonecrosis of the jaw (ONJ) in osteoporosis patients: report of delayed diagnosis of a multisite case and commentary about risks coming from a restricted ONJ definition[J]. Dent J (Basel), 2017,5(1): E13. [26] Ficat P, Arlet J.Dysplasias, osteoarthritis and osteonecrosis of the hip[J]. Sem Hop, 1974,50(8): 567. [27] 何悦. 下颌骨放射性骨坏死临床诊疗专家共识会议纪要[J].上海口腔医学,2017,26(4):398. [28] 刘继中, 纪宗玲, 陈苏民. OPG/RANKL/RANK系统与骨破坏性疾病[J]. 生物工程学报,2003,19(6):15-20. [29] 杨莹, 赵谦. OPG/RANKL/RANK系统及其在口腔颌面部骨破坏疾病中的研究进展[J].临床口腔医学杂志,2018, 34(6): 378-380. [30] Enciso R, Keaton J, Saleh N, et al.Assessing the utility of serum C-telopeptide cross-link of type 1 collagen as a predictor of bisphosphonate-related osteonecrosis of the jaw: A systematic review and meta-analysis[J]. J Am Dent Assoc, 2016,147(7):551-560. [31] Dal Prá KJ, Lemos CA, Okamoto R, et al.Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review[J]. Int J Oral Maxillofac Surg, 2017,46(2):151-156. [32] Liu J, Mattheos N, Su C, et al.The effects of Icariin on wound healing of extraction sites with administration of Zoledronic and Dexamethasone: A rat model study[J]. J Oral Pathol Med, 2017,47(2): 198-205. [33] Vilarinho J, Ferrare N, Moreira A, et al.Early bony changes associated with bisphosphonate-related osteonecrosis of the jaws in rats: A longitudinal in vivo study[J]. Arch Oral Biol, 2017,82:79-85. |